Randox Toxicology’s patented Biochip Array Technology offers the world’s first multiplex screening platform with excellent cross-reactivity and unrivalled limits of detection. It is designed to work across a variety of forensic matrices such as oral fluid, urine and whole blood. This revolutionary multi-analyte testing technology allows laboratories to achieve a complete toxicology profile from the initial screening phase.
Utilising our patented Biochip Array Technology, the Evidence Investigator has a comprehensive toxicology test menu and facilitates simultaneous detection of multiple drugs and drug metabolites from a single sample.
Our research and development team are advancing the future of toxicology testing as they continuously develop new and novel drugs of abuse tests enabling us to stay ahead of the ever-changing market. Randox Toxicology are first to market with a range of tests, including new psychoactive substances; AH-7921, U-47700 and MT-45 which are available on our NPS II panel.